购物车
- 全部删除
- 您的购物车当前为空
PCSK9-IN-10 是一种有效的,具有口服活性的PCSK9抑制剂,IC50值为 6.4 µM。PCSK9-IN-10 增加LDLR 蛋白的表达并降低 PCSK9 的表达。PCSK9-IN-10 可减缓动脉粥样硬化进展。PCSK9-IN-10 具有研究高脂血症的潜力。
为众多的药物研发团队赋能,
让新药发现更简单!
PCSK9-IN-10 是一种有效的,具有口服活性的PCSK9抑制剂,IC50值为 6.4 µM。PCSK9-IN-10 增加LDLR 蛋白的表达并降低 PCSK9 的表达。PCSK9-IN-10 可减缓动脉粥样硬化进展。PCSK9-IN-10 具有研究高脂血症的潜力。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 395 | 现货 | |
5 mg | ¥ 897 | 现货 | |
10 mg | ¥ 1,530 | 现货 | |
25 mg | ¥ 3,110 | 现货 | |
50 mg | ¥ 4,570 | 现货 | |
100 mg | ¥ 6,490 | 现货 | |
500 mg | ¥ 12,900 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 997 | 现货 |
产品描述 | PCSK9-IN-10, a potent and orally active inhibitor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), exhibits a half-maximal inhibitory concentration (IC50) of 6.4 µM. By enhancing the expression of Low-Density Lipoprotein Receptor (LDLR) protein and reducing PCSK9 expression, PCSK9-IN-10 effectively decreases atherosclerosis progression. This compound holds promise for hyperlipidemia research applications. |
靶点活性 | PCSK9:6.4 µM |
体外活性 | PCSK9-IN-10 (0, 2.5, 5, 12.5, 25 µM;24小时) 显著降低了PCSK9蛋白的表达,并以剂量依赖的方式提高了LDL受体(LDLR)的表达。[1] |
体内活性 | PCSK9-IN-10(30 mg/kg;口服;每日一次,持续8周)在ApoE KO小鼠中降低总胆固醇(TC)水平并减小动脉粥样硬化斑块的大小。[1] |
分子量 | 373.41 |
分子式 | C18H23N5O4 |
CAS No. | 368434-98-4 |
Smiles | COCCNc1nc2n(C)c(=O)n(C)c(=O)c2n1Cc1cccc(OC)c1 |
密度 | 1.32 g/cm3 (Predicted) |
存储 | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 225.0 mg/mL (602.6 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容